Sotagliflozin Can Reduce Risk of Death, Readmission at 90 Da

A posthoc analysis of the pivotal SOLOIST-WHF trial provides insight into the effects of sotagliflozin use on risk of cardiovascular mortality and heart failure readmissions at 90 days.

Related Keywords

Michigan , United States , Bertram Pitt , Craig Granowitz , Cardiometabolic Health Congress Bertram Pitt , Lexicon Pharmaceuticals , Drug Administration , University Of Michigan , School Of Medicine , Cardiometabolic Health Congress , Early Mortality , Heart Failure Related Events , Post Hoc Analysis ,